SumanaDevataMD
Hematology • Milwaukee, WIHematologic Oncology
Hematology/Oncology, University of Michigan
Dr. Devata is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9200 W Wisconsin Ave
Milwaukee, WI 53226Phone+1 414-805-4600Fax+1 414-805-4602
Education & Training
University of MichiganFellowship, Hematology and Medical Oncology, 2012 - 2015
Medical College of Wisconsin Affiliated HospitalsResidency, Internal Medicine, 2008 - 2011
Loyola University Chicago Stritch School of MedicineClass of 2008
Certifications & Licensure
WI State Medical License 2010 - 2025
MI State Medical License 2012 - 2022- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 4 citationsSocioeconomic disadvantage contributes to ethnic disparities in multiple myeloma survival: a matched cohort study.Christopher Staffi Buradagunta, Zhuping Garacci, Anita D'Souza, Binod Dhakal, Sumana Devata
Blood Cancer Journal. 2022-05-25 - 2 citationsClinical Availability of ATRA for Patients With Suspected Acute Promyelocytic Leukemia: Why Guidelines May Not Be Followed.Marcus Geer, Charles E. Foucar, Sumana Devata, Lydia L. Benitez, Anthony J. Perissinotti
Journal of the National Comprehensive Cancer Network. 2021-08-17 - 6 citationsImpact of initial chemotherapy regimen on outcomes for patients with double-expressor lymphoma: A multi-center analysis.Christopher D'Angelo, Walter Hanel, Yi Chen, Menggang Yu, David T. Yang
Hematological Oncology. 2021-08-04
Abstracts/Posters
- Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K _/_ Inhibitor in Patients with Relapsed/Refractory T-Cell LymphomaSumana Devata, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Ruxolitinib Is Active and Well Tolerated in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis: Preliminary Results of an Ongoing, Open-Label, Single Cen...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymph...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Contemporary Treatment Options for a Classical Disease: Advanced Hodgkin LymphomaFebruary 13th, 2020
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
